risperidone has been researched along with Parkinsonian Disorders in 13 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 72 patients with a first episode of schizophreniform psychosis (schizophrenia spectrum disorder) with less than 2 weeks of exposure to antipsychotic medication were randomized to quetiapine or risperidone in a single-blind 12-week controlled trial." | 9.14 | Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. ( Craig, TK; Elanjithara, T; Gafoor, R; Landau, S; McGuire, P; Power, P, 2010) |
| "Following an earlier study in which elderly patients with schizophrenia had their typical antipsychotic medication changed to olanzapine or risperidone, the 61 patients were followed for up to a further six months to see if either treatment was superior in terms of efficacy or side effects." | 9.12 | A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. ( Ames, D; Chiu, E; Hall, K; Halliday, G; Harrigan, S; Hassett, A; Hustig, H; MacFarlane, S; Mastwyk, M; Nagalingam, V; O'Connor, DW; Opie, J; Ritchie, CW; Snowdon, J, 2006) |
| "A total of 72 patients with a first episode of schizophreniform psychosis (schizophrenia spectrum disorder) with less than 2 weeks of exposure to antipsychotic medication were randomized to quetiapine or risperidone in a single-blind 12-week controlled trial." | 5.14 | Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. ( Craig, TK; Elanjithara, T; Gafoor, R; Landau, S; McGuire, P; Power, P, 2010) |
| "Following an earlier study in which elderly patients with schizophrenia had their typical antipsychotic medication changed to olanzapine or risperidone, the 61 patients were followed for up to a further six months to see if either treatment was superior in terms of efficacy or side effects." | 5.12 | A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. ( Ames, D; Chiu, E; Hall, K; Halliday, G; Harrigan, S; Hassett, A; Hustig, H; MacFarlane, S; Mastwyk, M; Nagalingam, V; O'Connor, DW; Opie, J; Ritchie, CW; Snowdon, J, 2006) |
| ": Among 5,391 individuals with parkinsonism who died during the study period (2002-2008) and a matched comparison group of 25,937 who were still alive, individuals exposed to atypical antipsychotic drugs had a higher risk of death (unadjusted odds ratio [OR] = 2." | 1.38 | Antipsychotics and mortality in Parkinsonism. ( Anderson, GM; Fischer, H; Gill, SS; Gruneir, A; Herrmann, N; Hyson, C; Marras, C; Rochon, PA; Wang, X, 2012) |
| "A large cohort of 1528 patients with parkinsonism was analyzed, gathering data on demography, motor and non-motor characteristics, as well as the final etiologic diagnoses based on established criteria." | 1.36 | The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. ( Munhoz, RP; Teive, HA; Werneck, LC, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Garzón, M | 3 |
| Angal, S | 3 |
| Rana, M | 3 |
| Bridel, C | 1 |
| Garibotto, V | 1 |
| Thomas Antérion, C | 1 |
| Convers, P | 1 |
| Desmales, S | 1 |
| Borg, C | 1 |
| Laurent, B | 1 |
| Bharadwaj, R | 1 |
| Grover, S | 1 |
| Chan, HY | 1 |
| Chang, CJ | 1 |
| Chiang, SC | 1 |
| Chen, JJ | 1 |
| Chen, CH | 1 |
| Sun, HJ | 1 |
| Hwu, HG | 1 |
| Lai, MS | 1 |
| Moncrieff, J | 1 |
| Cohen, D | 1 |
| Mason, JP | 1 |
| Munhoz, RP | 1 |
| Werneck, LC | 1 |
| Teive, HA | 1 |
| Gafoor, R | 1 |
| Landau, S | 1 |
| Craig, TK | 1 |
| Elanjithara, T | 1 |
| Power, P | 1 |
| McGuire, P | 1 |
| Marras, C | 1 |
| Gruneir, A | 1 |
| Wang, X | 1 |
| Fischer, H | 1 |
| Gill, SS | 1 |
| Herrmann, N | 1 |
| Anderson, GM | 1 |
| Hyson, C | 1 |
| Rochon, PA | 1 |
| Nakagawa, S | 1 |
| Koyama, T | 1 |
| Ritchie, CW | 1 |
| Chiu, E | 1 |
| Harrigan, S | 1 |
| MacFarlane, S | 1 |
| Mastwyk, M | 1 |
| Halliday, G | 1 |
| Hustig, H | 1 |
| Hall, K | 1 |
| Hassett, A | 1 |
| O'Connor, DW | 1 |
| Opie, J | 1 |
| Nagalingam, V | 1 |
| Snowdon, J | 1 |
| Ames, D | 1 |
| Czarnecki, K | 1 |
| Kumar, N | 1 |
| Josephs, KA | 1 |
| Chroni, E | 1 |
| Lekka, NP | 1 |
| Tsibri, E | 1 |
| Economou, A | 1 |
| Paschalis, C | 1 |
1 review available for risperidone and Parkinsonian Disorders
| Article | Year |
|---|---|
[Extrapyramidal syndrome].
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazep | 2003 |
3 trials available for risperidone and Parkinsonian Disorders
| Article | Year |
|---|---|
A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Dystonia; Female; Hu | 2010 |
Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia.
Topics: Adult; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Parkinsonian Disorders; Quetiapine Fum | 2010 |
A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Olanzapine; Parkinsonian Disorder | 2006 |
9 other studies available for risperidone and Parkinsonian Disorders
| Article | Year |
|---|---|
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Topics: Antipsychotic Agents; Fatigue; Humans; Parkinsonian Disorders; Risperidone | 2022 |
Teaching NeuroImages: Drug-induced parkinsonism with asymmetrical putaminal DaT binding.
Topics: Dopamine Plasma Membrane Transport Proteins; Humans; Infarction, Middle Cerebral Artery; Middle Aged | 2015 |
An odd manifestation of the Capgras syndrome: loss of familiarity even with the sexual partner.
Topics: Aged; Amnesia; Antipsychotic Agents; Atrophy; Brain; Capgras Syndrome; Donepezil; Hallucinations; Hu | 2008 |
Parkinsonism and akathisia with quetiapine: three case reports.
Topics: Adolescent; Antipsychotic Agents; Dibenzothiazepines; Female; Hallucinations; Humans; Parkinsonian D | 2008 |
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.
Topics: Adult; Affect; Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety Disorders; Attitude to Health; | 2009 |
The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics.
Topics: Aged; Antipsychotic Agents; Cinnarizine; Cohort Studies; Diagnosis, Differential; Female; Flunarizin | 2010 |
Antipsychotics and mortality in Parkinsonism.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Cohort Studies | 2012 |
Parkinsonism and tardive antecollis in frontotemporal dementia--increased sensitivity to newer antipsychotics?
Topics: Antipsychotic Agents; Benzodiazepines; Dementia; Dibenzothiazepines; Dystonia; Humans; Male; Middle | 2008 |
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Hepatolenticular Degeneratio | 2001 |